Abstract
Arginine availability as regulator of NO bioavailability has gained growing interest. We hypothesized that diabetes would induce NO deficiency in the renal medulla, with subsequent reduction in pO2, due to arginine limitation for NO production. Medullary NO, pO2 and blood flow were measured in control and streptozotocin-induced diabetic rats, with or without α-tocopherol treatment, during acute iv infusion of L-arginine followed by L-NAME. Components of the arginine metabolism were also investigated. Both untreated and tocopherol-treated diabetic rats had reduced NO compared to controls (59±4, n=10 and 67±7, n=7 vs. 122±7 nmol/l, n=8, respectively). Arginine increased NO in diabetic rats and not in controls, and totally restored NO in tocopherol-treated animals. Although blood flow increased equally in all groups, arginine selectively increased pO2 in diabetic rats. Diabetes decreased plasma arginine and ADMA concentrations, but increased hepatic CAT-2A and ornithine levels independent of tocopherol treatment. In conclusion, diabetic rats had reduced renomedullary NO and pO2, which was independent of hemodynamic changes but related to decreased plasma arginine due to increased hepatic arginine metabolism. Reduced oxidative stress augmented the NO response, but did not fully restore NO levels. These changes may be important factors for the development of diabetes-induced renal dysfunction.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have